Europe’s biopharmaceutical industry faces highest business risks among six key industry sectors, according to first-of-its-kind comparative study
26 November 2014 | By Janssen
Economic and societal value of Europe’s biopharmaceutical sector can only be sustained if risks to innovation are adequately rewarded, study concludes...